Clentiazem

Clentiazem

SCHEMBL6616493

COc1ccc([C@@H]2Sc3cc(Cl)ccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1

nearest known ligand 0.86

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1S Q13698 12/20 0.86
CYP3A4 P08684 3/20 0.77
TSHR P16473 2/20 0.77
ABCB11 O95342 2/20 0.77
LMNA P02545 2/20 0.77
KCNH2 Q12809 2/20 0.77
SLC22A1 O15245 1/20 0.77
CACNA1F O60840 1/20 0.77
ABCB1 P08183 1/20 0.77
HRH2 P25021 1/20 0.77
ADRA1A P35348 1/20 0.77
SCN1A P35498 1/20 0.77
SCN4A P35499 1/20 0.77
HTT P42858 1/20 0.77
SCN7A Q01118 1/20 0.77
CACNA1D Q01668 1/20 0.77
PLAUR Q03405 1/20 0.77
CACNA1C Q13936 1/20 0.77
SCN5A Q14524 1/20 0.77
SCN9A Q15858 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Clentiazem SCHEMBL33909 1.00 CACNA1S (0.86) CACNA1SCYP3A4TSHRABCB11LMNA
Clentiazem SCHEMBL7432489 1.00 CACNA1S (0.86) CACNA1SCYP3A4TSHRABCB11LMNA
Clentiazem SCHEMBL33910 1.00 CACNA1S (0.86) CACNA1SCYP3A4TSHRABCB11LMNA
Clentiazem SCHEMBL10830378 0.99 CACNA1S (0.85) CACNA1SCYP3A4TSHRABCB11LMNA
Clentiazem SCHEMBL10830375 0.99 CACNA1S (0.85) CACNA1SCYP3A4TSHRABCB11LMNA
Clentiazem SCHEMBL10830381 0.99 CACNA1S (0.85) CACNA1SCYP3A4TSHRABCB11LMNA
Clentiazem SCHEMBL9296639 0.96 CACNA1S (0.80) CACNA1SCYP3A4TSHRABCB11LMNA
Clentiazem SCHEMBL387183 0.95 CACNA1S (0.79) CACNA1SCYP3A4TSHRABCB11LMNA
Clentiazem SCHEMBL387182 0.95 CACNA1S (0.79) CACNA1SCYP3A4TSHRABCB11LMNA
Clentiazem SCHEMBL7266655 0.95 CACNA1S (0.79) CACNA1SCYP3A4TSHRABCB11LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1087953-B1 NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES NICOX SA (FR) 2004-11-17 EP claimed
EP-1087953-B1 NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES NICOX SA (FR) 2004-11-17 EP disclosed
US-20040147575-A1 Nitrate salts of antihypertensive medicines NICOX S.A. 2004-07-29 US disclosed
US-6645965-B1 Sildenafil, hydralazine, minoxidil, or zaprinast; cardiovascular disorders NICOX S.A. (FR) 2003-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147575-A1 Nitrate salts of antihypertensive medicines NOS2, NOS1, NOS3 CACNA1S 105/4885CYP3A4 277/4885TSHR 2825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.